---
title: "Varegacestat (AL102) in Desmoid tumors: Active surveillance"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Active surveillance. Topics: Active surveillance as the primary approach, Monitoring schedule and threshold for starting active treatment, Referral to experienced centers during active surveillance, Consensus update of June 2023: shift toward less-invasive management, and 8 further topics. 12 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description/active-surveillance"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Active surveillance

<a id="heading-2.2.2.1.1"></a>

## 2.2.2.1.1 Active Surveillance

<a id="topic-2.2.2.1.1-1"></a>

### Active surveillance as the primary approach

> “Active surveillance is the well-established primary approach to primary/recurrent sporadic/familial desmoid tumours (DT).”
> “Previously surgery was the standard primary treatment modality; however, in recent years a paradigm shift towards a more conservative management has been introduced”
> “Neither surgery nor other forms of active treatments are proposed as primary therapy at diagnosis. Considering the biology and unpredictable course of the disease, active treatments should be considered only in case of persistent progression.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.2.1.1-2"></a>

### Monitoring schedule and threshold for starting active treatment

> “Active surveillance means that patients need to be continuously monitored with a first MRI (or alternatively CT if MRI is not possible) within 1-2 months, then in 3-6 months intervals.”
> “A decision towards an active treatment should be postponed until the occurrence of subsequent progression or increase of symptoms burden, assessed with at least two further assessments and possibly not before one year from diagnosis in the absence of fulfilling RECIST progressive disease.”
> “However, when the disease is located close to a critical structure that may pose significant problems to the patient's life (such as mesenteric or head & neck DT) an earlier decision towards an active therapy may be taken simply because there is a potentially higher risk of morbidity prior to disease stabilisation.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.2.1.1-3"></a>

### Referral to experienced centers during active surveillance

> “Of note, patients not progressing for 2 years were very unlikely to need any further active treatment”
> “Clearly, patients need to be referred to centres with experience in DT to minimize the risk of active surveillance and avoid unnecessarily debilitating or mutilating surgery when possibly needed.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.2.1.1-4"></a>

### Consensus update of June 2023: shift toward less-invasive management

> “To update the 2020 global evidence-based consensus guideline on the management of patients with DT, the Desmoid Tumor Working Group convened a 1-day consensus meeting in Milan, Italy, on June 30, 2023”
> “Previously, surgery was the standard primary treatment modality; however, within the past decade, a paradigm shift toward less-invasive management has been introduced and an effort to harmonize the strategy among clinicians has been made.”
> “Selection of the appropriate strategy should consider DT-related symptoms, associated risks, tumor location, disease morbidities, available treatment options, and preferences of individual patients.”

Source: [Kasper et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38900421/)

<a id="topic-2.2.2.1.1-5"></a>

### Watch and wait as the front-line approach for newly diagnosed patients

> “Immediate surgery is no more the standard treatment of DF.”
> “There is clear consensus that a conservative watch and wait strategy should be the front-line approach to newly diagnosed patients, irrespective of existing pain or other clinical symptoms, offering a way to understand the behavior of the disease and tailor next treatment steps.”
> “The time interval for a watch and wait approach could be 1–2 years and patients should be closely followed, preferably using contrast enhanced MRI.”

Source: [Kasper et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5834048/)

<a id="topic-2.2.2.1.1-6"></a>

### Active surveillance in line with Desmoid Tumour Working Group and NCCN recommendations

> “Active Surveillance is increasingly being utilized as the initial treatment of choice (in line with recommendations from the Desmoid Tumour Working Group and NCCN),”
> “Active Surveillance may not be appropriate if progression could”
> “be life-threatening or pose a risk for mutilation (adjacent nerves or vessels).”
> “Patients should be monitored every 3-6mo initially, and if the disease is stable this can be extended.”

Source: [Alberta Health Services clinical practice guideline SAR-004 (2025)](https://www.ahs.ca/assets/info/hp/cancer/if-hp-cancer-guide-sar004-desmoid.pdf)

<a id="topic-2.2.2.1.1-7"></a>

### Pooled analysis of three prospective observational studies: treatment-free survival and progression

> “In this pooled analysis from three prospective observational studies on patients with extra-abdominal desmoid-type fibromatosis, we confirm that spontaneous regression occurs in a significant proportion of patients and that two-thirds are treatment free at 5 years.”
> “Patients (n = 282) with a median follow-up of 53 months (IQR, 39–63) were included. The 3- and 5-year TFS rates were 67% and 66%, respectively; the 3- and 5-year crude cumulative incidences were 33% and 34% for RECIST progression, 26% and 34% for RECIST regression, and 33% and 38% for regression post-RECIST progression, respectively.”
> “The 3- and 5-year PFS rates (95% CI) were 54% (48%–60%) and 51% (45%–58%), respectively”
> “In total, 93 of 282 (33.0%) patients received AT after initial AS, of which 45 (48.4%) patients received AT after RECIST progression, and 48 (54.6%) patients received AT after symptomatic progression alone.”
> “The specific mutation (S45F), larger tumor size, and extremity and trunk locations were all associated with a lower probability of spontaneous RECIST regression.”

Source: [Colombo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11788647/)

<a id="topic-2.2.2.1.1-8"></a>

### Prospective multicenter observational study of peripheral primary sporadic tumors

> “This prospective, multicenter, observational study (NCT01801176) included patients ≥18 years of age with primary sporadic DF located in an extremity or the abdominal/thoracic wall.”
> “Between 2012 and 2015, 100 patients were enrolled.”
> “Median follow-up was 46.6 months (IQR 36.8-61.1) and the 3-year PFS was 53.4% (95% confidence interval 43.5-63.1%). At progression (48 patients), 23 patients received active treatment.”
> “Fifty-eight patients (58%) presented with spontaneous tumor regression (decrease > 0% compared with the initial size) during the first 3 months (n = 35, 35%) or after an initial progression (n = 23, 23%), of whom 26 (26%) had partial responses (PRs).”

Source: [Bonvalot et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37777684/)

<a id="topic-2.2.2.1.1-9"></a>

### Italian prospective multicenter observational study at any site

> “This is an Italian prospective, multicenter, observational study (NCT02547831) including patients ≥16 years with primary sporadic DF at any site.”
> “At 32.3-month median follow-up, 42 of 108 (39%) showed RECIST progression. Spontaneous regression was initially observed in 27 of 108 (25%), while it followed dimensional progression in another 33 of 108 (31%). PFS at 36 months was 54.5% [95% confidence interval (CI), 44.9%-66.1%]. Thirty-five of 108 (32%) patients received active treatment, 18 of 108 (17%) after RECIST progression and 17 of 108 (15%) after symptomatic progression. TFS at 36 months was 65.9% (95% CI, 57.3%-75.9%).”

Source: [Colombo et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35247923/)

<a id="topic-2.2.2.1.1-10"></a>

### GRAFITI prospective cohort study of non-intraabdominal tumors

> “In this multicenter prospective cohort study (NTR4714), adult patients with non-intraabdominal DTF were followed during an initial AS approach for 3 years.”
> “A total of 105 patients started with AS.”
> “At 3 years, cumulative incidence of the start of active treatment was 30% (95% confidence interval [CI] 21–39) and PFS was 58% (95% CI 49–69). Median time to start active treatment and PFS were not reached at a median follow-up of 33.7 months. During AS, 32% of patients had stable disease, 28% regressed, and 40% demonstrated initial progression.”
> “Larger tumor size (≥5 cm; hazard ratio = 2.38 [95% CI 1.15–4.90]) and S45F mutation (hazard ratio = 6.24 [95% CI 1.92–20.30]) were associated with the start of active treatment.”
> “The follow-up protocol of the GRAFITI trial consisted of follow-up visits and imaging examinations (Ultrasound [US] and MRI) at baseline, 3,6,9,12,18,24, and 36 months (window ±3 months).”

Source: [Schut et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9994811/)

<a id="topic-2.2.2.1.1-11"></a>

### Single sarcoma reference center cohort at all anatomic locations

> “Patients with a primary desmoid tumor at any anatomic location diagnosed between 1998 and 2016 were identified in a prospectively maintained database from a single sarcoma reference center in the United Kingdom.”
> “The study identified 168 patients with a primary desmoid tumor initially managed with active surveillance.”
> “Of all the patients, 36% experienced radiologic progressive disease, 36% had stable disease, and 27% regressed.”
> “Eventually, 46% of the patients proceeded to treatment. The median time to start of treatment after initial surveillance was 31 months, whereas the median follow-up time for the patients not receiving any treatment was 40.5 months. The indications for initiation of treatment were pain (32%), progression (31%), or both (13%).”

Source: [van Houdt et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31531797/)

<a id="topic-2.2.2.1.1-12"></a>

### Use of active surveillance before treatment among survey participants

> “Following a confirmed diagnosis of DT, a total of 383 participants completed the treatment survey, with 136 (36%) reporting active surveillance before treatment initiation.”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

Additional sources: [Gronchi et al. (2021)](https://www.annalsofoncology.org/article/S0923-7534%2821%2902184-0/fulltext); [Salas et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21844500/)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
